Tags

Type your tag names separated by a space and hit enter

Inhibition by salbutamol of GHRH-induced GH release in type 1 diabetes mellitus.
Horm Metab Res. 1992 Nov; 24(11):520-3.HM

Abstract

Patients with type 1 diabetes mellitus (IDDM) show augmented GH secretion, which is implicated in the pathogenesis of microvascular complications. On the other hand, it is well known that beta-adrenergic receptors have inhibitory influence on GH secretion, likely via stimulation of hypothalamic somatostatin. Since the possibility of pharmacological suppression of GH secretion would be of value in IDDM, we investigated the effect of salbutamol (SAL, 4 mg orally at -60 min) on the GH response to GHRH (1 micrograms/kg iv at 0 min) in 6 well-controlled (mean HbA1c +/- SEM: 7.3 +/- 0.5%) patients with IDDM. Salbutamol was able to inhibit basal GH levels (p < 0.05) as well as to abolish the GHRH-induced GH rise. After SAL administration, a significant (p < 0.05) reduction of glucagon levels was also found. Our data show that the enhancement of beta 2 adrenergic activity by oral therapeutical doses of SAL inhibits basal and GHRH-stimulated GH secretion in patients with IDDM.

Authors+Show Affiliations

Department of Clinical Pathophysiology, University, of Turin, Italy.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

1333441

Citation

Martina, V, et al. "Inhibition By Salbutamol of GHRH-induced GH Release in Type 1 Diabetes Mellitus." Hormone and Metabolic Research = Hormon- Und Stoffwechselforschung = Hormones Et Metabolisme, vol. 24, no. 11, 1992, pp. 520-3.
Martina V, Miola C, Maccario M, et al. Inhibition by salbutamol of GHRH-induced GH release in type 1 diabetes mellitus. Horm Metab Res. 1992;24(11):520-3.
Martina, V., Miola, C., Maccario, M., Talliano, M., Arvat, E., Ghigo, E., & Camanni, F. (1992). Inhibition by salbutamol of GHRH-induced GH release in type 1 diabetes mellitus. Hormone and Metabolic Research = Hormon- Und Stoffwechselforschung = Hormones Et Metabolisme, 24(11), 520-3.
Martina V, et al. Inhibition By Salbutamol of GHRH-induced GH Release in Type 1 Diabetes Mellitus. Horm Metab Res. 1992;24(11):520-3. PubMed PMID: 1333441.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Inhibition by salbutamol of GHRH-induced GH release in type 1 diabetes mellitus. AU - Martina,V, AU - Miola,C, AU - Maccario,M, AU - Talliano,M, AU - Arvat,E, AU - Ghigo,E, AU - Camanni,F, PY - 1992/11/1/pubmed PY - 1992/11/1/medline PY - 1992/11/1/entrez SP - 520 EP - 3 JF - Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme JO - Horm. Metab. Res. VL - 24 IS - 11 N2 - Patients with type 1 diabetes mellitus (IDDM) show augmented GH secretion, which is implicated in the pathogenesis of microvascular complications. On the other hand, it is well known that beta-adrenergic receptors have inhibitory influence on GH secretion, likely via stimulation of hypothalamic somatostatin. Since the possibility of pharmacological suppression of GH secretion would be of value in IDDM, we investigated the effect of salbutamol (SAL, 4 mg orally at -60 min) on the GH response to GHRH (1 micrograms/kg iv at 0 min) in 6 well-controlled (mean HbA1c +/- SEM: 7.3 +/- 0.5%) patients with IDDM. Salbutamol was able to inhibit basal GH levels (p < 0.05) as well as to abolish the GHRH-induced GH rise. After SAL administration, a significant (p < 0.05) reduction of glucagon levels was also found. Our data show that the enhancement of beta 2 adrenergic activity by oral therapeutical doses of SAL inhibits basal and GHRH-stimulated GH secretion in patients with IDDM. SN - 0018-5043 UR - https://www.unboundmedicine.com/medline/citation/1333441/Inhibition_by_salbutamol_of_GHRH_induced_GH_release_in_type_1_diabetes_mellitus_ L2 - http://www.thieme-connect.com/DOI/DOI?10.1055/s-2007-1003379 DB - PRIME DP - Unbound Medicine ER -